Thomas R. Alessi

Continuous subcutaneous delivery of exenatide via ITCA 650 leads to sustained glycemic control and weight loss for 48 weeks in metformin-treated subjects with type 2 diabetes

Robert R. Henry, Julio Rosenstock, Douglas Logan et al. · Journal of Diabetes and its Complications · 2014 · 79 citations · Full text

Medicine, Pharmacology, Pharmacotherapy +17

Synthetic studies directed toward naturally occurring cyclooctanoids. 2. A stereocontrolled assembly of (.+-.)-pleuromutilin via a remarkable sterically demanding oxy-Cope rearrangement

Robert K. Boeckman, Dane M. Springer, Thomas R. Alessi · Journal of the American Chemical Society · 1989 · 60 citations

Natural Sciences, Chemistry, Medicinal Chemistry +8

Randomized Trial of Continuous Subcutaneous Delivery of Exenatide by ITCA 650 Versus Twice-Daily Exenatide Injections in Metformin-Treated Type 2 Diabetes

Robert R. Henry, Julio Rosenstock, Douglas Logan et al. · Diabetes Care · 2013 · 43 citations · Full text

Medicine, Endocrinology, Pharmacology +11

DUROS® Technology Delivers Peptides and Proteins at Consistent Rate Continuously for 3 to 12 Months

Catherine M. Rohloff, Thomas R. Alessi, Bing Yang et al. · Journal of Diabetes Science and Technology · 2008 · 42 citations · Full text

Pharmacy, Bioengineering, Pharmaceutics +17

Randomized Study of Antihypertensive Efficacy and Safety of Combination Aliskiren/Valsartan vs Valsartan Monotherapy in Hypertensive Participants With Type 2 Diabetes Mellitus

George L. Bakris, Suzanne Oparil, Das Purkayastha et al. · Journal of Clinical Hypertension · 2012 · 39 citations · Full text

Pharmacy, Pharmacology, Pharmacotherapy +17